OBJECTIVE: To uncover the influence of plasmacytoma variant translocation 1 (PVT1) on aggravating the progression of glioma via downregulating UPF1.
PATIENTS AND METHODS: The relative levels of PVT1 and UPF1 in glioma tissues were determined. PVT1 level in glioma patients in stage I+II and stage III+IV, and either with metastasis or not was examined as well. The Kaplan-Meier curves were depicted for assessing the survival in glioma patients expressing a high and low level of PVT1. The regulatory effects of PVT1 and UPF1 on the proliferative and migratory abilities of U87 and LN229 cells were evaluated. The subcellular distributions of PVT1 and UPF1 were analyzed, and their interaction was investigated by performing RNA immunoprecipitation (RIP) assay. At last, the mRNA level of UPF1 was determined in U87 and LN229 cells overexpressing PVT1 treated with 50 μM α-amanitin.
RESULTS: PVT1 was upregulated in glioma tissues relative to controls. Its level was higher in glioma patients with advanced stage or accompanied by metastasis. The glioma patients with a high level of PVT1 suffered a worse prognosis. The overexpression of PVT1 accelerated proliferative and migratory abilities of U87 and LN229 cells. UPF1 was conversely downregulated in glioma patients. Its level was negatively correlated to that of PVT1. The overexpression of UPF1 attenuated the proliferative and migratory abilities of U87 and LN229 cells. Both PVT1 and UPF1 were mainly enriched in the cytoplasm. The interaction between PVT1 and UPF1 was identified in the RIP assay. PVT1 prolonged the half-life of UPF1 and inhibited its synthesis.
CONCLUSIONS: PVT1 accelerates the proliferative and migratory abilities of glioma via downregulating UPF1.
To cite this article
Z.-H. Lv, Z.-Y. Wang, Z.-Y. Li
LncRNA PVT1 aggravates the progression of glioma via downregulating UPF1
Eur Rev Med Pharmacol Sci
Vol. 23 - N. 20